First, we demonstrated that acalabrutinib potently inhibited BTK activity and downstream effectors in CLBL1, a canine B-cell lymphoma cell line, and primary canine lymphoma cells. This evidence concerns the gene BTK and B-cell non-Hodgkin lymphoma.